C4 Therapeutics (CCCC) Other Accumulated Expenses (2019 - 2022)

C4 Therapeutics' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $309000.0 for Q1 2022.

• On a quarterly basis, Other Accumulated Expenses fell 65.16% year-over-year to $309000.0 in Q1 2022; TTM through Mar 2022 was $309000.0, a 65.16% decrease from a year earlier, with the FY2021 full-year figure at $413000.0, down 11.94% from the prior year.
• Other Accumulated Expenses declined to $309000.0 in Q1 2022 per CCCC's latest filing, from $413000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $887000.0 in Q1 2021 and bottomed at $164000.0 in Q3 2020.
• The 4-year median for Other Accumulated Expenses is $294500.0 (2019), against an average of $370750.0.
• Across the five-year window, Other Accumulated Expenses surged 67.5% in 2020 and plunged 65.16% in 2022, its largest moves.
• Year by year, Other Accumulated Expenses stood at $280000.0 in 2019, then jumped by 67.5% to $469000.0 in 2020, then decreased by 11.94% to $413000.0 in 2021, then fell by 25.18% to $309000.0 in 2022.
• Per Business Quant, the three latest CCCC Other Accumulated Expenses figures stand at $309000.0 (Q1 2022), $413000.0 (Q4 2021), and $201000.0 (Q3 2021).